Señales en vivo de IMAB | Maximiza tus Ganancias con Getagraph.com

COMPRAR 116148 min ago

@ CNY1.720

Emitido: 13 feb 2024 @ 09:31

Retorno: 2.33%

Señal anterior: feb 9 - 10:06

Señal anterior: Vender

Retorno: -6.01 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	126 330
Volumen promedio	347 658
Capitalización de mercado	135.56M
EPS	CNY0 ( 2024-03-29 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-0.720
ATR14	CNY0.00400 (0.23%)

Volumen Correlación

Largo: 0.05 (neutral)

Corto: -0.44 (neutral)

Signal:(45.7) Neutral

I-Mab Correlación

10 Correlaciones Más Positivas
ATNX	0.884
CGO	0.88
BPRN	0.88
GFAI	0.874
DRCT	0.853
CFRX	0.848
BELFA	0.842
APLD	0.84
CNTY	0.838
CVCY	0.834

10 Correlaciones Más Negativas
RMRM	-0.883
GOODM	-0.814
DWSH	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

I-Mab Correlación - Moneda/Commodity

-0.51
( weak negative )

-0.16
( neutral )

0.00
( neutral )

0.64
( weak )

I-Mab Finanzas

Annual	2023
Ingresos:	CNY27.64M
Beneficio Bruto:	CNY27.64M (100.00 %)
EPS:	CNY-16.53

FY	2023
Ingresos:	CNY27.64M
Beneficio Bruto:	CNY27.64M (100.00 %)
EPS:	CNY-16.53

FY	2022
Ingresos:	CNY-221.56M
Beneficio Bruto:	CNY-248.80M (112.29 %)
EPS:	CNY-31.75

FY	2021
Ingresos:	CNY88.03M
Beneficio Bruto:	CNY41.59M (47.25 %)
EPS:	CNY-29.19

Financial Reports:

No articles found.

I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.